MaxCyte, Inc. (MXCT)
MaxCyte, Inc.
9713 Key West Avenue
Suite 400
Rockville, MD 20850
United States
301 944 1700
https://www.maxcyte.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 143
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Maher Masoud | President, CEO & Director | 650.98k | N/D | 1976 |
| Mr. Douglas Arthur Doerfler | Founder | 2.34M | N/D | 1956 |
| Mr. Douglas J. Swirsky CFA, CPA | Chief Financial Officer | 607.42k | N/D | 1969 |
| Mr. Jay Gelfman | Senior Vice President of Operations | N/D | N/D | N/D |
| Mr. Ronald Evan Holtz CPA, Ph.D. | Executive Vice President of Administration | 649.38k | N/D | 1958 |
| Mr. David Sandoval | Senior Vice President, General Counsel & Corporate Secretary | N/D | N/D | N/D |
| Mr. Thomas Michael Ross | Executive Vice President of Global Sales | N/D | N/D | 1961 |
| Mr. Jack Horgan | Vice President of Corporate Development | N/D | N/D | N/D |
| Ms. Jill Mayer | Senior Vice President of Human Resources | N/D | N/D | N/D |
| Dr. J. Stark Thompson Ph.D. | Consultant | 84.71k | N/D | 1942 |
Descripción
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Gestión corporativa
La calificación ISS Governance QuickScore de MaxCyte, Inc. a partir del 1 de mayo de 2024 es 6. Las puntuaciones principales son Auditoría: 2; Junta: 8; Derechos del accionista: 8; Compensación: 7.
